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use, inexpensive, scalable, defi ned, and capable of delivering 
a product with predictable performance and long “shelf life.” 
There have been a number of approaches developed, including 
the use of differential cytokine or chemical combinations, 
3D cell aggregation, and perfused devices, to mimic the liver 
niche and architecture. [ 17–20 ] While these approaches marked 
signifi cant progress, their complexity and/or undefi ned nature 
has limited large-scale deployment of the technology. In order 
to tackle this issue, we hereby report on the use of a defi ned 
biopolymer substrate in conjunction with a serum-free differen-
tiation procedure with both research and good manufacturing 
practice (GMP) grade PSCs. Importantly, those stem-derived 
populations displayed robust and predictable performance in 
cell culture which was hallmarked by gene expression of matrix 
metalloproteinase 13 (MMP13), delta catenin (CTNND2), and 
thrombospondin 2 (THBS2). 
 H9 human embryonic stem cells (hESCs), displaying an 
appropriate morphology and expressing stem cell markers 
(Oct-4 and Nanog, SSEA-4, TRA-1–60, and TRA-1–81) were 
expanded and used for the differentiation experiments. Impor-
tantly, SSEA-1 expression was minimal in these populations 
(Figure S1A–D, Supporting Information). Additionally, hESCs 
were able to spontaneously differentiate to all the three germ 
layers and directly differentiate to HLCs (Figure S1E, Supporting 
Information and  Figure  1 ). Following validation, hESC popula-
tions were directly differentiated to hepatoblasts using a defi ned 
procedure. [ 20 ] Stem cell–derived hepatoblasts were removed 
from their substrate and replated, under serum-free conditions, 
onto a chemically defi ned polyurethane surface (PU). At 10, 15, 
and 20 d postreplating, hepatocyte differentiation status was 
studied by immunostaining for a marker of hepatocyte differ-
entiation, HNF4α, and dedifferentiation, vimentin. Stem cell–
derived hepatocytes expressed stable levels of HNF4α on the 
PU for up to 20 d in culture (Figure  1 A). The converse was true 
for Matrigel (MG) cultures which began to deteriorate from 
day 15 onward, and by day 20 approximately fourfold fewer 
cells expressed HNF4α (22% ± 1.8) (Figure  1 B). The loss of the 
hepatocyte phenotype was also corroborated by staining for a 
marker of hepatocellular dedifferentiation. Stem cell–derived 
HLCs replated on PU expressed low levels of vimentin, ranging 
from 23% to 35% (Figure  1 A). In contrast, stem cell–derived 
hepatocytes on MG demonstrated greater dedifferentiation, 
with staining ranging from 54% to 78% (Figure  1 B). These 
results were further supported by immunostaining studies 
 The ability to generate renewable sources of human soma, 
from defi ned genetic backgrounds, has enormous potential for 
modern medicine, with immediate impacts being the delivery 
of tailor-made models of human tissue “in a dish,” and the 
delivery of cell-based therapies likely to follow. Theoretically, 
pluripotent stem cells (PSCs) can give rise to all somatic cell 
types found in the human body, [ 1 ] with their self-renewal and 
differentiation properties offering the prospect of generating 
unlimited quantities of human cells for biomedical application. 
Our particular interest lies in the delivery of human hepatocyte 
like cells (HLCs) derived from PSCs. Numerous hepatocyte dif-
ferentiation protocols have been established using 2D and 3D 
cell culture, [ 2 ] and encouragingly, the stem cell–derived HLCs 
produced exhibit many typical hepatocyte characteristics. [ 3–15 ] 
While these attributes are promising, the HLCs produced are 
immature in status, reminiscent of fetal or neo-natal hepato-
cytes. [ 16 ] One major obstacle to stem cell–derived HLC matura-
tion has been cellular instability in culture. Notably, the use of 
undefi ned or xenobiotic culture components has contributed to 
variable cell performance, making it diffi cult to unravel the com-
plexity behind hepatocyte differentiation and dedifferentiation. 
 Therefore, the development of highly defi ned cell based 
systems are required if the true potential of stem cell–derived 
HLCs is to be realized. Such systems should be simple to 
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examining human albumin and cytochrome P450 3A (CYP3A) 
expression (Figure S2, Supporting Information). hESC-derived 
HLCs differentiated on PU generated cell populations that 
were 86% (±4%) and 88% (±1.7%) positive for albumin and 
CYP3A, respectively, 20 d postreplating. This was an approxi-
mate twofold improvement compared with MG cultures, with 
43% (±9.5%) and 44% (±8.8%) cells positive for albumin and 
CYP3A, respectively. The immunostaining studies were further 
supported by functional analysis. Analysis of cytochrome P450 
activity revealed a 30-fold increase in CYP3A activity and a nine-
fold increase in the CYP1A2 activity in cells cultured on PU 
(Figure  1 C,D). The ability to secrete albumin was also improved 
threefold in HLCs differentiated on PU (Figure  1 E). The 
improved differentiation status of the stem cell–derived HLCs 
generated under defi ned conditions was further supported 
by their response to compounds which measure hepatocyte 
metabolic capacity (Figure S3, Supporting Information). Stem 
cell–derived HLCs differentiated on PU displayed consistent 
performance in response to two compounds, BMS-827278-01 
and BMS-835981-01, which require metabolic activation, via 
CYP2D6, to toxic endpoints. This was in contrast to HLCs dif-
ferentiated using MG surfaces which exhibited less consistent 
performance, presumably due to defi ciencies in the CYP2D6 
metabolic pathway (Figure S3, Supporting Information). 
 Given the superior performance of HLCs under defi ned 
conditions, we were keen to identify genes important in 
this process. We therefore employed PCR array technology 
to screen for candidate genes. The RT 2 Profi ler PCR array 
profi led the expression of 84 genes important for cell–cell 
and cell–matrix interactions. Stem cell–derived HLCs differ-
entiated on MG and PU (20 d postreplating) were compared 
and from these studies, we identifi ed increased expression of 
six genes: ADAMTS13, NCAM1, CTNND2, THBS2, MMP10, 
and MMP13, on PU ( Figure  2 A,B and Table S4, Supporting 
Information). The output of the array was validated by real 
time quantitative PCR (qPCR). One of the candidate genes, 
ADAMTS13, was not amplifi ed to the same extent and was 
therefore was excluded from further studies (Figure  2 C). The 
remaining genes were found to be enriched three to sixfold 
in HLCs differentiated on PU. In order to understand the 
role each gene played in hepatocyte function, we employed 
small interfering RNA (siRNA) technology to knockdown 
the target gene products. HLCs were transfected twice over 
a 48 h period during differentiation (days 13–15). Post-
transfection, gene knockdown was assessed by qPCR. Gene 
knockdown was dependent on the siRNA used. NCAM1 and 
CTNND2 levels decreased by ≈25%, MMP10 levels fell by 
≈40%, MMP13 decreased by ≈60%, while THBS2 levels fell 
by ≈75% ( Figure  3 A) after transfection. In response to gene 
knockdown, albumin secretion fell by ≈30% and ≈50% in cells 
transfected with siRNAs to CTNND2 and MMP13, respec-
tively (Figure  3 B). Whereas, CYP3A function was reduced by 
≈25% and ≈30% in response to the knockdown of THBS2 and 
MMP13, respectively (Figure  3 C). These studies demonstrated 
that THBS2, MMP13, and CTNND2 are important in stabi-
lizing HLC phenotype under defi ned conditions. 
Adv. Healthcare Mater. 2015, 
DOI: 10.1002/adhm.201500391
www.advhealthmat.de
www.MaterialsViews.com
 Figure 1.  Serum-free hepatocyte differentiation of hESCs on a defi ned polyurethane surface (PU), and a biological matrix Matrigel (MG). A,B) Expres-
sion of hepatocyte nuclear factor 4α, (HNF4α - red), and the dedifferentiation marker vimentin (green) in hESC-derived hepatocytes maintained on 
PU or MG at different time points during the differentiation procedure. Cell nuclei were counterstained with DAPI (blue). IgG controls demonstrate 
the specifi city of immunostaining. The yield percentage of positive cells was calculated from fi ve random fi elds of view containing at least 400 cells 
each. Data are expressed as mean ± SD. Images are taken at 20× magnifi cation. Scale bar represents 100 µm. C,D) HLC cytochrome P450 3A and 1A2 
(CYP3A and CYP1A2) activity maintained on PU or MG during differentiation. Units of activity are expressed as relative light units (RLU) mL −1 mg −1 
of protein. E) Albumin production was detected by ELISA and expressed as micrograms of albumin mL −1 24 h −1 mg −1 . Data represent mean ± SD 
( n = 3).* P < 0.05, ** P < 0.01, *** P < 0.001. Images were taken at 20× and the scale bar represents 100 µm.
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 The manufacture of stem cell–derived somatic cells is 
likely to play an important part in developing cell based ther-
apies of the future. To be able to deliver clinical grade mate-
rials, one must use clinical grade components. In this vein, 
we employed two hESC lines which were derived under GMP 
conditions, Man 11 and Man 12. Both Man lines were char-
acterized in detail, displaying typical hESC morphology and 
expressing Oct-4 and Nanog. hESC surface maker expres-
sion was also detected by fl ow cytometry. Man 11 and Man 
12 hESCs expressed SSEA-4, TRA-1–60, and TRA-1–81, but not 
SSEA-1 (Figure S4A–C, Supporting Information). Addition-
ally, both hESC lines were able to spontaneously form three 
germ layers and directly differentiate to HLCs (Figures S4D 
and S5, Supporting Information). Encouragingly, Man 11 and 
Man 12 differentiation was highly effi cient, with 87% and 95% 
of the Man 11 derived HLCs expressing HNF4α and albumin, 
respectively. The pattern of expression was similar for Man 
12 derived HLCs, with 84% and 99% of derived hepatocytes 
expressing HNF4α and albumin, respectively (Figure S5, Sup-
porting Information). Following basic characterization, hESCs 
were differentiated toward the hepatocyte lineage. Cytochrome 
P450 activity, albumin and alpha-fetoprotein (AFP) produc-
tion was measurable in HLCs maintained on PU for at least 
15 d postreplating (Figure  3 D,F,G and Figure S6A, Supporting 
Information). At this point stem cell–derived HLCs expressed 
greater levels of MMP13, CTNND2, and THBS2 than their MG 
counterparts (Figure  3 E and Figure S6B, Supporting Informa-
tion). There were differences recorded in the gene expression 
between Man 11 and Man 12 HLCs. CTNND2 expression was 
marginally increased and MMP 13 expression was reduced in 
Man 11 HLCs in comparison to Man 12 HLCs (Figure  3 E and 
Figure S6B, Supporting Information). THBS2 was expressed at 
similar levels in both Man 11 and Man 12 HLCs. In addition to 
changes in gene expression, we also observed differences in the 
stability of Man 11 and Man 12 HLCs. Man 12 HLCs, like their 
H9 counterparts, were stable for up to 20 d on the PU surface. 
At this point albumin production was stable, 
while the production of AFP decreased 
approximately fi vefold over the same 5 d 
time frame. In these experiments, Man 11 
derived HLCs were only stable up to 15 d in 
culture, and therefore could not be character-
ized past this point (Figure S6A, Supporting 
Information). 
 The ability to differentiate and maintain 
human somatic cells in culture has revolu-
tionary potential. However, the delivery of 
reliable and stable human models is a major 
barrier limiting current endeavors. The devel-
opment of defi ned differentiation systems, 
free of xenobiotic materials or undefi ned 
additives, is required to achieve this objective. 
We developed an interdisciplinary approach, 
blending polymer chemistry, and defi ned 
biological differentiation systems. The focus 
of our studies was to identify novel genetic 
signatures associated with stable hepatocyte 
differentiation from both research and GMP 
grade hESC lines (Figure  1 and Figure S3, 
Supporting Information). In a focused survey of human cell 
membrane components and receptors, using a PCR array, we 
identifi ed fi ve genes which were enhanced in cells differenti-
ated in a defi ned culture environment. Those genes, which 
appear to be new markers of hepatocyte differentiation, could 
be broadly divided in two categories; extracellular matrix (ECM) 
remodelers (MMP10 and MMP13) or cell–cell and cell–matrix 
interactors (THBS2, CTNND2, and NCAM1) (Figure  2 ). The 
MMPs are a family of proteins known to display substrate 
specifi city for particular ECMs. Their activity is regulated by 
post-translational modifi cations and by the tissue inhibitor 
of matrix metalloproteinases (TIMPs). [ 21 ] MMPs are essen-
tial for normal remodeling of the extracellular matrix, tissue 
morphogenesis, and wound healing. [ 21 ] Our analysis indicated 
that both MMP13 and 10 gene expression was increased over 
cultures differentiated in an undefi ned manner. It is possible 
that differences in gene expression may refl ect the capacity of 
the cell to remodel the ECM which is known to be important 
in the maintenance of hepatocyte phenotype. [ 22–24 ] In addition 
to its role in collagen remodeling, we identifi ed MMP13 as a 
potential regulator of cytochrome P450 metabolism and human 
albumin secretion (Figure  3 ). Our analyses also demonstrated 
increased expression of genes which code for proteins involved 
in cell–cell and cell–matrix interactions. THBS2, CTNND2, and 
NCAM1 were expressed at greater levels in cell populations dif-
ferentiated under defi ned conditions. THBS2 and CTNND2 are 
known to regulate cell adhesion, organization, and migration, 
in response to growth factor stimulation. [ 25–27 ] Along similar 
lines, NCAM1 has been identifi ed as important in cell motility, 
liver development and liver regeneration. [ 28 ] In addition to their 
proposed roles in cell attachment, organization, and migration, 
we report our novel fi ndings: a reduction in THBS2 expres-
sion led to reduced cytochrome P450 function, while reduced 
CTNND2 led to reduced albumin secretion (Figure  3 B,C). Our 
further experiments focused on the functional gene signature 
MMP13, THBS2, and CTNND2. In these studies, we employed 
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 Figure 2.  Differential gene expression of HLCs maintained on PU or MG. A) The scatter 
plot represents expression of the major ECM components and matrix associated receptors 
expressed in human cells. The scatter plot represents threefold change in gene expression. 
Symbols outside the boundary areas indicate fold-differences greater or lesser than threefold. 
B) Graph representing the induced genes in hESC-derived HLCs maintained on PU. C) qPCR 
was employed to validateon the upregulated genes identifi ed on the array. Data represent mean 
± SD ( n = 3). ** P < 0.01, *** P < 0.001 versus Matrigel.
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two hESC lines derived to GMP and subsequently maintained 
serum free. Notably, defi ned and directed differentiation of 
both GMP lines yielded cell populations which expressed 
increased levels of MMP13, THBS2, and CTNND2 and thereby 
supporting data derived from the research grade hESC line. Of 
note the Man 12 derived HLCs performed best in culture, dem-
onstrating stable albumin production and a fi vefold reduction 
in AFP secretion over the same 5 d period. These results imply 
that Man 12 HLCs were maturing in culture as HLC phenotype 
stabilized. 
 In conclusion, dependable differentiation from pluripotent 
stem cells requires defi ned culture parameters. Such systems 
will permit informative and mechanistic analysis of human 
biology. The novel gene signature identifi ed in these studies is 
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 Figure 3.  Role of the candidate genes in HLCs function. A) Graph representing the decrease of candidate genes in HLCs post-siRNA transfection. 
B) HLC albumin production, post-siRNA transfection, was detected by ELISA. Data represent the mean ± SD ( n = 3). * P < 0.05 versus scrambled 
control. C) HLC CYP3A activity, post-siRNA transfection, was determined using the pGlo system. Units of activity are expressed as relative light 
units (RLU) mL −1 mg −1 of protein. Data represent the mean ± SD ( n = 3). *** P < 0.001 versus scrambled control. D) Man 11 and Man 12 derived 
HLCs maintained on PU display CYP3A activity at day 15 postreplating. Units of activity are expressed as RLU mL −1 mg −1 of protein. Data represent 
the mean ± SD ( n = 3). E) Candidate genes upregulated in Man 12 HLCs on PU at day 15 postreplating. Data represent the mean ± SD ( n = 3). 
*** P ≤ 0.001 versus Matrigel. F,G) Man 12 derived HLCs maintained on PU secrete albumin and AFP at days 15 and 20 postreplating. Units of activity 
are expressed as nanograms of albumin or AFP mL −1 24 h mg −1 . Data represent mean ± SD ( n = 3). * P < 0.05 versus day 15 HLCs.
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one example, which may also serve as important gold standard 
parameters for quality control and manufacture of GMP grade 
products at scale. 
 Experimental Section 
 Cell Culture and Differentiation : hESCs H9 (WARF), Man 11 and 
Man 12 (University of Manchester) were cultured and differentiated to 
hepatoblasts as reported previously. [ 20 ] At day 8 in the differentiation 
process the cells were cultured in HepatoZYME-SFM media (Life 
Technologies) supplemented with 10 × 10 −6  M hydrocortisone 
21-hemisuccinate (Sigma) and 2 × 10 −3  M GlutaMAX (Gibco) containing 
10 ng mL −1 hepatocyte growth factor and 20 ng mL −1 oncostatin 
M (Peprotech) for 24 h cells. At day 9 stem cell–derived hepatoblasts 
were removed from their substrate using 5 min at 37 °C incubation 
with TrypLE (Life Technologies). Following this, HLCs were plated 
onto an optimized PU polymer surface [ 29 ] or Matrigel (BD Biosciences, 
San Jose) coated surfaces in HepatoZYME-SFM supplemented with 
5% KnockOut Serum Replacement (Life Technologies), containing 
20 ng mL −1 hepatocyte growth factor, 40 ng mL −1 oncostatin M, and 
10 ng mL −1 EGF (Peprotech). 48 h postreplating the HepatoZYME-SFM 
was supplemented with 10 ng mL −1 hepatocyte growth factor and 
20 ng mL −1 oncostatin M. The media was changed every 48 h until the 
experimental endpoint. 
 RNA Isolation and qPCR : Total RNA was prepared using the RNAeasy 
Mini Kit (Qiagen, UK) according to manufacturer's instructions. Total 
RNA was reverse transcribed using QuantiTect Reverse Transcription 
Kit (Qiagen), as per manufacturer's instructions (Qiagen). Quantitative 
PCR was carried out using Taqman Fast Advance Mastermix and 
appropriate primers (Applied Biosystems). The primers are listed in 
Table S1 (Supporting Information). The samples were analyzed using 
Roche LightCycler 480 Real-Time PCR System. Results were normalized 
to GAPDH and expressed as relative expression over the control sample. 
Quantitative PCRs were run in triplicate. Data analysis was performed 
using Roche LightCycler 480 Software (version 1.5). 
 PCR Array : Reverse transcription (RT) of RNA samples used 
on the PCR array was performed using RT 2 First Strand Kit, as per 
manufacturer's instructions (Qiagen). Real-time PCR reactions were 
performed using RT 2 Profi ler PCR array (Qiagen) in a 384-well optical 
plates. Real-time reactions were conducted on an ABI 7900HT (Applied 
Biosystems). Results were PCR reactions performed in duplicate for 
each target gene. The gene expression was analyzed by RT 2 Profi ler PCR 
array Data Analysis version 5.0 (Qiagen) in the form of cycle threshold 
(Ct) values. 
 Cell Transfection : hESC-derived HLCs were transfected for two 
consecutive days (day 13 and day 14) postreplating using the 
Silencer Select siRNAs (Life Technologies). siRNAs were used at a 
fi nal concentration of 80 × 10 −6  M diluted in Opti-MEM I containing 
Lipofectamine 2000 (Life Technologies). The siRNA are listed in Table S2 
(Supporting Information). Cells were collected at day 15 postreplating 
for further analysis. Each knockdwon was perfromed in triplicate and 
scrambled RNA controls were used throughout. 
 Cytochrome P450 Functional Assay : CYP3A and CYP1A2 activity were 
measured using the pGlo kit from Promega and the assays were carried 
out as per the manufacturer’s instructions (http://www.promega.com/
tbs/tb325/tb325.pdf). CYP activities were expressed as relative light 
units (RLU), per mg −1 of protein per mL−1 of tissue culture medium. 
 Measurement of Secreted Albumin : hESC-derived HLCs were cultured 
in HepatoZYME-SFM. The supernatants were collected for analysis by 
ELISA (Alpha Diagnostic International) and the data was expressed as 
micrograms (µg) or nanograms (ng) of albumin or AFP per mL −1 , per 
24 hours, per mg −1 of protein. 
 Immunofl uorescence : Cell cultures at different points during cellular 
differentiation were fi xed in 100% methanol (Sigma-Aldrich) at 
−20 °C for 30 min. Postfi xation, cell monolayers were washed three 
times with PBS for 5 min at room temperature. After blocking with 
PBS/0.1%Tween/10% BSA for 1 h, the cells were incubated with 
primary antibodies diluted in PBS/0.1%Tween/1% BSA overnight 
at 4 °C. Following this the cells were washed three times with 
PBS/0.1%Tween/1% BSA and then incubated with the appropriate 
secondary antibody diluted in PBS/0.1%Tween/1% BSA for 1 h at 
room temperature. Following this the cells were washed twice with 
PBS/0.1%Tween/1% BSA and once with PBS. Fixed and stained 
monolayers were then stained with DAPI (Life Technologies) for 
20 min at room temperature. Following this cultures were mounted 
with PermaFluor aqueous mounting medium (Thermo Scientifi c). The 
cells were analyzed using a Zeiss Axio Observed Z1 microscope and 
processing Zeiss Axiovison Rel 4.8 software. The percentage of positive 
cells and standard deviation was estimated from at least fi ve random 
fi elds of view with a least 400 cells per fi eld of view. The primary and 
secondary antibodies are listed in Table S3 (Supporting Information). 
 Supporting Information 
 Supporting Information is available from the Wiley Online Library or 
from the author. 
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